Return to homepagePandemic Pact

SCARLETRED Holding GmbH

  • Funded by Austrian Research Promotion Agency (FFG)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    Austrian Research Promotion Agency (FFG)

  • Research Location

    Austria

  • Lead Research Institution

    SCARLETRED Holding GmbH

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

KLIPHA-COVID19: Use of recombinant human superoxide dismutase (rhSOD) in the treatment of severe pneumonia and SARS in COVID-19 patients. DE SCARLETRED's rhSOD (recombinant human superoxide dismutase) treatment of COVID-19 pneumonia offers a first therapeutic approach which directly targets the inflammatory cascade in the lungs and other organs by increasing the elimination of radical oxygen species (ROS). This is intended to counteract further damage caused by COVID-19 in the lungs and other organs.